nvax... che volumi

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
8.664
Punti reazioni
313
questo non l'avevo previsto, voleranno mazzate....

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes​


NEWS PROVIDED BY
Novavax, Inc.
Dec 14, 2022, 16:15 ET

GAITHERSBURG, Md., Dec. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the "notes"). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering of the notes, Novavax expects to grant to the initial purchasers a 30-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes.
The notes will represent senior unsecured obligations of Novavax and will accrue interest payable semi-annually in arrears and will mature on December 15, 2027, unless earlier converted, redeemed or repurchased. Novavax will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.01 per share ("common stock"), or a combination of cash and shares of its common stock, at Novavax' election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Novavax' option at any time, and from time to time, on or after December 22, 2025, if the last reported sale price of common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which Novavax provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.
J.P. Morgan, Jefferies and Cowen are acting as joint book-running managers and representatives of the initial purchasers for the offering of the notes. J. Wood Capital Advisors served as financial advisor to the Company in relation to the offering of the notes.
Concurrently with the offering of notes, Novavax also announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock at the public offering price, less underwriting discounts and commissions. The offering of the notes is not contingent upon the consummation of the concurrent common stock offering, and the concurrent common stock offering is not contingent upon the consummation of the offering of the notes.
Novavax may use the net proceeds from the offering of the notes and, if consummated, the concurrent common stock offering, for general corporate purposes, including but not limited to the continued global commercial launch of Nuvaxovid, repayment or repurchase of a portion of the $325 million in outstanding principal amount of our 3.75% convertible senior unsecured notes due February 1, 2023, working capital, capital expenditures, research and development expenditures, clinical trial expenditures, repayments under our supply agreements, as well as acquisitions and other strategic purposes.
The offer and sale of the notes are not being registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. The notes may not be offered or sold in the U.S. except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws.
The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
 

francesco1962

Nuovo Utente
Registrato
26/3/19
Messaggi
8.795
Punti reazioni
147
Era da comprare in open a 9,5 $, ma voglio passare un weekend tranquillo :o.... adesso 10,20 $ :cool:....
 

ale1970

Nuovo Utente
Registrato
21/10/20
Messaggi
156
Punti reazioni
9
Ne ho prese 30 @9.6 giusto per gradire.
Ma ne avevo prese anche ieri 30 @11..6
Quindi alla fine non sono ancora in pari :nono:
Certo che con questa non ti annoi:D
 

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
8.664
Punti reazioni
313
Era da comprare in open a 9,5 $, ma voglio passare un weekend tranquillo :o.... adesso 10,20 $ :cool:....
nvaxacq.jpg


fatto, pmc attuale 13,13 -16,17%, ho azzardato ed è andata bene, un meno 16% dopo il -30 di ieri mi sembrava un pò esagerato
 

francesco1962

Nuovo Utente
Registrato
26/3/19
Messaggi
8.795
Punti reazioni
147
Azz....+16% :eek:....ma ci sono news sulle condizioni dell'offering, o cosa!? :confused:....
 

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
8.664
Punti reazioni
313
Azz....+16% :eek:....ma ci sono news sulle condizioni dell'offering, o cosa!? :confused:....
una botta di vita, in realtà l'unica notizia recente è di ieri ed è questa:

Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock.

Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
Dec 28, 2022
GAITHERSBURG, Md., Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027 (the "Notes"), and on December 23, 2022, the Company completed the closing of the initial purchasers' option to purchase up to an additional $25.25 million aggregate principal amount of the Notes, which was exercised in full. On December 20, 2022, the Company also completed the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase up to an additional 975,000 shares of its common stock (the "Common Stock Offering") resulting in total gross proceeds of $74.75 million. Total combined gross proceeds to the Company from both the offering of Notes and the Common Stock Offering was $250 million.
The Notes were offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). J.P. Morgan, Jefferies and Cowen acted as joint book-running managers and representatives of the initial purchasers for the offering of the Notes. J. Wood Capital Advisors served as financial advisor to the Company in relation to the offering of the Notes.
The Notes bear cash interest at a rate of 5.00%, payable on June 15 and December 15 of each year, beginning on June 15, 2023. The Notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Novavax' option at any time, and from time to time, on or after December 22, 2025, if the last reported sale price of Novavax' common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which Novavax provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. The Notes are convertible at an initial conversion rate of 80.0000 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of $12.50 per share of Novavax' common stock, representing a 25% conversion premium of the public offering price in the Company's concurrent common stock offering that closed on December 20, 2022. The Company will settle conversions by paying or delivering, as applicable, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election.
Novavax estimates that the net proceeds from the offering of the Notes are approximately $166.3 million, after deducting the initial purchasers' discounts and commissions and estimated offering expenses.
The offer and sale of the Notes and any shares of common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.
For the Common Stock Offering, shares were issued at $10.00 per share, resulting in total gross proceeds from the Common Stock Offering of $74.75 million before deducting the underwriters' discount and offering expenses. J.P. Morgan, Jefferies and Cowen acted as joint book-running managers and representatives of the underwriters for the Common Stock Offering. B. Riley Securities and H.C. Wainwright & Co. acted as co-lead managers for the Common Stock Offering.
Novavax estimates that the net proceeds from the Common Stock Offering are approximately $69.8 million, after deducting the underwriters' discounts and commissions and estimated offering expenses.
A registration statement relating to the Common Stock Offering was filed with the Securities and Exchange Commission ("SEC") on March 11, 2020, and is effective. The Common Stock Offering was made by means of a prospectus supplement and the accompanying prospectus. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the Common Stock Offering are available on the SEC's website at www.sec.gov, and may also be obtained from: J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com.
 

francesco1962

Nuovo Utente
Registrato
26/3/19
Messaggi
8.795
Punti reazioni
147
Chiusura dell'offerta pubblica con l'emissione di nuove azioni ordinarie a 10$ e di obbligazioni convertibili con rendimento al 5% con cedola semestrale, che prevedono, a discrezione della società, o il rimborso del valore nominale se la quotazione delle azioni sul mercato sarà per un certo numero di sedute consecutive almeno il 130% del prezzo di conversione concordato, oppure, appunto, la conversione al prezzo di 12,50$ ad azione (80 shares ogni 1.000$ di valore nominale delle obbligazioni), a partire da dicembre 2025 ;)....
 
Ultima modifica:

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
8.664
Punti reazioni
313
anche VXRT sale del 20%, non sarà per le notizie che arrivano dalla CIna ?
 

SonoPresente

Tesla P.T. $485+/-3%
Registrato
12/9/11
Messaggi
5.889
Punti reazioni
200
Buonasera a tutti

Tranquilli che Nvax non sbarcherà in Cina ... almeno credo